Articles Related to Human epidermal growth factor receptor 2
Drug Therapy Problems and Clinical Outcomes Among Patients with Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer on Trastuzumab-Based Therapy in a Kenyan Tertiary Health Facility
Breast cancer ranks first among the most commonly diagnosed cancers in Kenyan females and globally. Treatment is
challenging because it is a heterogeneous disease with several subtypes. There has been a significant change in the treatment of Human
Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer subtypes following the introduction and widespread use of HER2
targeted therapies.
Liquid Biopsy in Advanced Gastric Malignancy and Molecular Targeted Therapy; a Case Report and Update Pertaining Anti HER2-Neu Therapy
Human epidermal growth factor receptor 2 (HER2) is responsible for the pathogenesis and poor outcomes of several types of cancers, including advanced gastric and gastroesophageal junction cancer. Molecular-targeted drugs on the other hand, such as trastuzumab, prolong overall survival and progression-free survival in HER2-positive gastric cancer. The purpose of the case report is to evaluate the impact of delivering trastuzumab in advanced gastric cancer with concomitant HER2 mutation and amplification.